Citizens Maintains Market Outperform on CRISPR Therapeutics (CRSP) Despite Casgevy Slowdown

Core Insights - CRISPR Therapeutics AG (NASDAQ:CRSP) is identified as a top short squeeze stock, with Citizens maintaining a Market Outperform rating and an $86 price target as of November 11 [1] - Positive findings from CRISPR's presentation at the American Heart Association regarding CTX310, which targets ANGPTL3 for cholesterol-related issues, have contributed to optimism [1][2] - The company has several upcoming catalysts, including updates on in-vivo cardiovascular projects and a pediatric review for Casgevy scheduled for 2025 [2] Financial Performance - In the third quarter, Casgevy sales were reported at $17 million, significantly below the consensus estimate of $41 million, with infusions decreasing from 16 in the second quarter to 10 [3] - Despite the sales shortfall, CRISPR remains optimistic about the Casgevy launch, noting an increase in cell collection numbers from 25 in the second quarter to 45 [3] Company Overview - CRISPR Therapeutics AG is recognized as a leader in gene-editing technology, utilizing its proprietary gene sequencing platform to develop precise treatments for diseases requiring DNA modification [4]